
Panojeb IV 40mg Injection
Marketer
Kembris Pharmaceuticals
Salt Composition
Pantoprazole (40mg)
Overview Panojeb IV 40mg Injection
AcidEase 40mg intravenous injection diminishes gastric acid production. It's indicated for acid-related gastrointestinal disorders including reflux disease, peptic ulcers, and Zollinger-Ellison syndrome, offering symptomatic relief and facilitating healing. AcidEase 40mg is also prophylactic against stress ulcers in critically ill patients and is used pre-anesthesia to mitigate aspiration risks. Classified as a proton pump inhibitor (PPI), this medication is intravenously administered by a healthcare provider only when deemed clinically superior to oral formulations. Dosage and treatment duration are individualized, determined by your condition and response. Consistent use, as directed, is crucial even with rapid symptom resolution. Dietary modifications – smaller, more frequent meals, avoidance of caffeine, spicy, and fatty foods – enhance treatment efficacy. Common, usually mild, adverse events include nausea, vomiting, headache, dizziness, gas, diarrhea, abdominal pain, and thrombophlebitis (vein inflammation). Persistent or bothersome side effects warrant medical attention. Prolonged use (over one year) may elevate fracture risk, particularly at higher doses; discuss bone health (osteoporosis) prevention strategies, such as calcium and vitamin D supplementation, with your doctor. Consult your physician before use if you have severe hepatic impairment, are on HIV medication, have prior PPI allergies, or suffer from osteoporosis. Pregnant or lactating individuals should also seek medical advice. Alcohol consumption should be avoided due to its acid-stimulating effect. Refrain from operating machinery if dizziness or drowsiness occurs.
Primary Ingredients of Panojeb IV 40mg Injection
No text provided. Please provide the text you want me to rephrase.
Uses of Panojeb IV 40mg Injection
Managing gastroesophageal reflux, peptic ulcers, and Zollinger-Ellison syndrome.
Major Benefits of Panojeb IV 40mg Injection:
Administering this medication will be handled by your healthcare provider. Self-medication is strongly discouraged.
Common Side effects of Panojeb IV 40mg Injection:
- Diarrhea
- Flatulence
- Headache
- Joint pain
- Nausea
- Stomach pain
- Vomiting
- Dizziness
- Thrombophlebitis
How to use Panojeb IV 40mg Injection:
Administering this medication will be handled by your healthcare provider. Self-medication is strongly discouraged.
How Panojeb IV 40mg Injection works:
Evaprost 40mg IV injection, a proton pump inhibitor, decreases gastric acid secretion, thereby alleviating heartburn and acid indigestion.
SAFETY ADVICE
AlcoholUNSAFE
Combining Panojeb IV 40mg Injection and alcohol is dangerous.
PregnancyCONSULT YOUR DOCTOR
Administering Panojeb IV 40mg Injection during pregnancy may pose risks. While human data is scarce, animal research indicates potential harm to the fetus. A physician will assess the advantages against possible risks prior to prescribing. Seek medical advice.
Breast feedingSAFE IF PRESCRIBED
Administration of Panojeb IV 40mg Injection while breastfeeding is likely safe. Available human data indicate minimal risk to the infant.
DrivingCONSULT YOUR DOCTOR
The effect of Panojeb IV 40mg Injection on driving ability is undetermined. Refrain from driving if you develop symptoms impairing concentration or reaction time.
KidneySAFE IF PRESCRIBED
For patients with kidney impairment, the 40mg intravenous Panojeb injection is considered safe and requires no dosage modification.
LiverCAUTION
Administering Panojeb IV 40mg Injection requires careful consideration in individuals exhibiting severe hepatic impairment. Dosage modification of Panojeb IV 40mg Injection might be necessary. Physician consultation is advised.
What if you forget to take Panojeb IV 40mg Injection :
Omitting a scheduled dose of Panojeb IV 40mg Injection warrants immediate physician consultation.
Facts to Know About Panojeb IV 40mg Injection
| Label | Value |
|---|---|
| Chemical Category | Benzimidazole Sulfoxide |
| Developing Habits | No. |
| Treatment Category | Gastrointestinal system |
| Behavioral Class | Gastric acid suppressants |
